Quantcast
Last updated on April 23, 2014 at 16:13 EDT

Latest Endo Health Solutions Inc. Stories

2014-04-17 08:28:06

DUBLIN, April 17, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) ("Endo" or the "Company") announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI"), has received requisite tenders and consents in connection with its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019 (the "2019 Existing EHSI Notes"), 7.00% Senior Notes due 2020 (the "2020 Existing EHSI Notes") and 7¼% Senior...

2014-04-11 08:24:42

DUBLIN, April 11, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) ("Endo" or the "Company") announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI"), has further extended the consent date and expiration date in its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7¼% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes"),...

2014-04-08 08:31:30

DUBLIN, April 8, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) ("Endo" or the "Company") announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI"), has amended the terms of its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7¼% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes"), for new unsecured 7.00% Senior Notes...

2014-03-28 00:23:19

DUBLIN, March 28, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) ("Endo" or the "Company") announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI"), will commence offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7¼% Senior Notes due 2022 issued by EHSI, which have an aggregate principal amount outstanding of $1.3 billion (collectively, the "Existing EHSI Notes"), for new...

2014-02-28 12:27:50

DUBLIN, Feb. 28, 2014 /PRNewswire/ -- -- Accretive transaction accelerates Endo's transformation into a leading specialty healthcare company -- Creates a compelling financial and operational platform for future growth -- Establishes Endo's global pharmaceuticals footprint -- Endo Health Solutions Inc. becomes Endo International plc Endo International plc (Nasdaq: ENDP; TSX: ENL), formerly Endo Health Solutions Inc., announced today that it has completed...

2014-02-28 08:24:24

MALVERN, Pa., Feb. 28, 2014 /PRNewswire/ -- -- Company expects to close Paladin Labs transaction on February 28, 2014. -- Full year 2013 adjusted diluted EPS exceeds previously issued guidance by $0.04. -- Total quarterly revenues of $585 million, reported diluted (GAAP) loss per share of $6.74 and adjusted diluted EPS of $0.96. -- Company expects 2014 revenues to be in the range from $2.50 billion to $2.62 billion. -- Company expects 2014...

2014-02-27 20:22:56

/PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) today announced that Ivan P. Gergel, executive vice president research & development and chief scientific officer, will be leaving the Company. Dr. Gergel will continue in his current role until March 31, 2014. MALVERN, Pa., Feb 27, 2013 Rajiv De Silva, president and chief executive officer of Endo, said, "I want to thank Ivan for his dedicated service and significant contributions to our R&D organization over...

2014-02-26 12:26:21

MALVERN, Pa., Feb. 26, 2014 /PRNewswire/ -- Endo Health Solutions Inc. (NASDAQ: ENDP) ("Endo") today announced that, at the shareholder meeting held today, proposals related to Endo's proposed acquisition of Paladin Labs Inc. (TSX: PLB) ("Paladin") were approved by Endo's shareholders. As previously announced, on November 5, 2013, Endo and Paladin entered into an arrangement agreement pursuant to which each of Endo and Paladin will be acquired by a new Irish holding company, Endo...

2014-02-21 12:24:58

MALVERN, Pa., Feb. 21, 2014 /PRNewswire/ -- Endo Pharmaceuticals, a subsidiary of Endo Health Solutions Inc. (Nasdaq: ENDP), announced today that it has reached a resolution of criminal and civil claims with the federal and participating state authorities and the District of Columbia regarding a previously disclosed investigation concerning past US sales, marketing and promotional practices related to Endo Pharmaceuticals Inc. product Lidoderm®. Under the agreement, the company...

2014-02-20 16:24:58

MALVERN, Pa., Feb. 20, 2014 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) will announce its fourth quarter 2013 financial results before the open of the U.S. financial markets on February 28, 2014 and members of its senior management team will host a conference call and webcast at 8:30 a.m. ET that day. Investors and other interested parties may call 866-515-2910 (domestic) or +1 617-399-5124 (international) and enter passcode 79916686. Please dial in 10 minutes prior to the...